ATCC is the premier global biological materials resource and standards organization. Founded in 1925, it has established itself as a leader in the Biotechnology, Health Care, and Manufacturing industries. ATCC is dedicated to providing the global scientific community with credible, advanced model systems to support complex research and innovations in basic science, drug discovery, translational medicine, and public health. The company recently received a significant $87.00M grant investment on 04 January 2024 from the Biomedical Advanced Research and Development Authority (BARDA). This injection of capital will likely fortify ATCC's position as a major player in the field. With its headquarters in Manassas, Virginia, and a research and technology center of excellence in Gaithersburg, Maryland, ATCC continues to expand its influence as a mission-driven, trusted partner that supports and encourages scientific collaboration. ATCC's extensive history of scientific contributions spanning nearly a century, and its unmatched collection of biological reference materials and data, position it as a valuable resource for academia, industry, and government. Through its products, services, and partnerships, ATCC remains committed to providing essential support to the scientific community. For more information, visit atcc.org.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Grant | $87.00M | 1 | Biomedical Advanced Research and Development Authority (BARDA) | 04 Jan 2024 |
Grant | $5.50M | 1 | Defense Threat Reduction Agency (DTRA) | 15 Feb 2022 |
No recent news or press coverage available for ATCC.